Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

DNA vaccines encoding the human papillomavirus type-16 (HPV-16) E6 and E7 oncoproteins genetically fused to the human herpes simplex virus type 1 (HSV-1) gD protein were tested in mice for induction of T cell-mediated immunity and protection against tumor cell challenge. Hybrid genes, generated after insertion of E6 or E7-encoding sequences into internal sites of the gD-encoding gene, were transcribed in vitro and the chimeric proteins were expressed at the surface of in vitro-transfected mammalian cells. Female C57BL/6 mice immunized with 4 intramuscular doses (100 microg of DNA/dose) of the DNA vaccines encoding E7 efficiently generated E7-specific CD8(+) T cells. Vaccination of mice with the DNA vaccines encoding the E7, or both E6 and E7, conferred complete protection to challenges from TC-1 tumor cells and partial therapeutic effect (40%) in mice inoculated with TC-1 cells on the same day or 5 days prior to the first vaccine dose.

Original publication




Journal article


Microbes Infect

Publication Date





1541 - 1550


Animals, CD8-Positive T-Lymphocytes, Cytokines, Cytoplasm, Disease Models, Animal, Female, Flow Cytometry, Herpesvirus 1, Human, Herpesvirus Vaccines, Human papillomavirus 16, Humans, Interferon-gamma, Membrane Proteins, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Neoplasms, Experimental, Oncogene Proteins, Viral, Papillomavirus E7 Proteins, Papillomavirus Infections, Papillomavirus Vaccines, Recombinant Fusion Proteins, Repressor Proteins, Vaccines, DNA, Viral Envelope Proteins, Viral Vaccines